Novelion Therapeutics Stock Price, News & Analysis (NASDAQ:NVLN)

$3.64 0.14 (4.00 %)
(As of 12/11/2017 02:43 AM ET)
Previous Close$3.50
Today's Range$3.45 - $3.66
52-Week Range$3.25 - $12.12
Volume128,100 shs
Average Volume99,619 shs
Market Capitalization$67.89 million
P/E RatioN/A
Dividend YieldN/A
Beta0.56

About Novelion Therapeutics (NASDAQ:NVLN)

Novelion Therapeutics logoNovelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

Receive NVLN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVLN
CUSIPN/A
Phone604-707-7000

Debt

Debt-to-Equity Ratio6.53%
Current Ratio1.45%
Quick Ratio1.28%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.57 million
Price / Sales5.00
Cash FlowN/A
Price / CashN/A
Book Value$7.33 per share
Price / Book0.50

Profitability

Trailing EPS($6.99)
Net Income$-52,870,000.00
Net Margins-108.10%
Return on Equity-57.36%
Return on Assets-11.88%

Miscellaneous

Employees163
Outstanding Shares18,650,000

Novelion Therapeutics (NASDAQ:NVLN) Frequently Asked Questions

What is Novelion Therapeutics' stock symbol?

Novelion Therapeutics trades on the NASDAQ under the ticker symbol "NVLN."

How were Novelion Therapeutics' earnings last quarter?

Novelion Therapeutics Inc. (NASDAQ:NVLN) released its quarterly earnings results on Tuesday, November, 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. Novelion Therapeutics had a negative net margin of 108.10% and a negative return on equity of 57.36%. During the same period in the previous year, the company earned ($0.05) EPS. View Novelion Therapeutics' Earnings History.

When will Novelion Therapeutics make its next earnings announcement?

Novelion Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for Novelion Therapeutics.

Where is Novelion Therapeutics' stock going? Where will Novelion Therapeutics' stock price be in 2017?

2 equities research analysts have issued 1-year price targets for Novelion Therapeutics' shares. Their forecasts range from $8.00 to $8.00. On average, they expect Novelion Therapeutics' share price to reach $8.00 in the next year. View Analyst Ratings for Novelion Therapeutics.

Are investors shorting Novelion Therapeutics?

Novelion Therapeutics saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,208,207 shares, an increase of 34.9% from the October 13th total of 895,554 shares. Based on an average daily volume of 125,874 shares, the short-interest ratio is currently 9.6 days. Currently, 7.2% of the company's shares are sold short.

Who are some of Novelion Therapeutics' key competitors?

Who are Novelion Therapeutics' key executives?

Novelion Therapeutics' management team includes the folowing people:

  • Jason M. Aryeh, Independent Chairman of the Board (Age 48)
  • Michael Dennis Price, Chief Financial Officer, Senior Vice President (Age 59)
  • Gregory D. Perry, Chief Financial and Administrative Officer (Age 56)
  • Jeffrey S. Hackman, Chief Operating Officer, Executive Vice President (Age 55)
  • Barbara Y. Chan, Chief Accounting Officer (Age 53)
  • Suzanne Louise Bruhn Ph.D., Director (Age 53)
  • Mark H.N. Corrigan M.D., Director (Age 60)
  • Mark A. DiPaolo, Director
  • Kevin Kotler, Director
  • John J. Orloff M.D., Director (Age 59)

Who owns Novelion Therapeutics stock?

Novelion Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (9.79%), Highbridge Capital Management LLC (4.60%), Schwab Charles Investment Management Inc. (0.73%) and OxFORD Asset Management LLP (0.15%). Company insiders that own Novelion Therapeutics stock include Donald K Stern, Jason Aryeh and Stonepine Capital, LP. View Institutional Ownership Trends for Novelion Therapeutics.

Who sold Novelion Therapeutics stock? Who is selling Novelion Therapeutics stock?

Novelion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC, Stonepine Capital Management LLC and OxFORD Asset Management LLP. View Insider Buying and Selling for Novelion Therapeutics.

Who bought Novelion Therapeutics stock? Who is buying Novelion Therapeutics stock?

Novelion Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc.. Company insiders that have bought Novelion Therapeutics stock in the last two years include Donald K Stern, Jason Aryeh and Stonepine Capital, LP. View Insider Buying and Selling for Novelion Therapeutics.

How do I buy Novelion Therapeutics stock?

Shares of Novelion Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novelion Therapeutics' stock price today?

One share of Novelion Therapeutics stock can currently be purchased for approximately $3.64.

How big of a company is Novelion Therapeutics?

Novelion Therapeutics has a market capitalization of $67.89 million and generates $13.57 million in revenue each year. The biotechnology company earns $-52,870,000.00 in net income (profit) each year or ($6.99) on an earnings per share basis. Novelion Therapeutics employs 163 workers across the globe.

How can I contact Novelion Therapeutics?

Novelion Therapeutics' mailing address is 887 GREAT NORTHERN WAY SUITE 250, VANCOUVER A1, V5T 4T5. The biotechnology company can be reached via phone at 604-707-7000 or via email at [email protected]


MarketBeat Community Rating for Novelion Therapeutics (NVLN)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  197
MarketBeat's community ratings are surveys of what our community members think about Novelion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novelion Therapeutics (NASDAQ:NVLN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.00$8.00$9.00$10.00
Price Target Upside: 81.41% upside81.41% upside11.25% upside1.19% downside

Novelion Therapeutics (NASDAQ:NVLN) Consensus Price Target History

Price Target History for Novelion Therapeutics (NASDAQ:NVLN)

Novelion Therapeutics (NASDAQ:NVLN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017Royal Bank Of CanadaLower Price TargetSector Perform$9.00 -> $8.00N/AView Rating Details
6/19/2017Bloom BurtonReiterated RatingAccumulateLowView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Novelion Therapeutics (NASDAQ:NVLN) Earnings History and Estimates Chart

Earnings by Quarter for Novelion Therapeutics (NASDAQ:NVLN)

Novelion Therapeutics (NASDAQ NVLN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018        
8/8/20176/30/2017($0.09)($0.13)$36.86 million$40.90 millionViewListenView Earnings Details
3/15/201712/31/2016($0.50)($1.76)$40.10 million$13.57 millionViewN/AView Earnings Details
11/1/2016Q316($0.12)($0.11)ViewN/AView Earnings Details
5/5/2016Q116($0.09)($0.41)ViewN/AView Earnings Details
2/25/2016Q415($0.09)($0.06)ViewN/AView Earnings Details
10/29/2015Q3($0.10)($0.05)ViewN/AView Earnings Details
7/30/2015Q2($0.09)($0.21)ViewN/AView Earnings Details
4/30/2015Q115($0.06)($0.12)ViewN/AView Earnings Details
2/26/2015Q414($0.09)($0.05)ViewN/AView Earnings Details
10/28/2014Q314($0.12)($0.10)ViewN/AView Earnings Details
8/5/2014Q214($0.12)($0.17)ViewN/AView Earnings Details
4/30/2014Q114($0.11)($0.13)ViewN/AView Earnings Details
2/28/2014Q413($0.14)($0.10)ViewN/AView Earnings Details
11/7/2013Q313($0.11)($0.15)ViewN/AView Earnings Details
8/1/2013Q213($0.10)($0.12)ViewN/AView Earnings Details
5/2/2013Q113($0.14)($0.13)ViewN/AView Earnings Details
2/21/2013Q412($0.22)($0.18)ViewN/AView Earnings Details
11/7/2012Q312($0.22)($0.25)$9.60 millionViewN/AView Earnings Details
8/2/2012($0.23)($0.33)ViewN/AView Earnings Details
5/3/2012($0.20)($0.21)ViewN/AView Earnings Details
2/23/2012($0.20)$0.04ViewN/AView Earnings Details
7/28/2011($0.13)($0.12)ViewN/AView Earnings Details
5/5/2011($0.15)($0.17)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Novelion Therapeutics (NASDAQ:NVLN) Earnings Estimates

Current Year EPS Consensus Estimate: $-8.95 EPS
Next Year EPS Consensus Estimate: $-5.67 EPS

Dividends

Novelion Therapeutics (NASDAQ:NVLN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/18/2013special$3.926/28/20136/24/20136/27/2013
(Data available from 1/1/2013 forward)

Insider Trades

Novelion Therapeutics (NASDAQ NVLN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.10%
Institutional Ownership Percentage: 75.55%
Insider Trades by Quarter for Novelion Therapeutics (NASDAQ:NVLN)
Institutional Ownership by Quarter for Novelion Therapeutics (NASDAQ:NVLN)

Novelion Therapeutics (NASDAQ NVLN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/12/2017Donald K SternDirectorBuy2,500$9.10$22,750.00View SEC Filing  
5/15/2017Jason AryehDirectorBuy361$8.95$3,230.95View SEC Filing  
9/15/2016Stonepine Capital, L.P.Major ShareholderBuy133,496$1.55$206,918.80View SEC Filing  
12/29/2015Jason AryehDirectorBuy18,400$2.50$46,000.00View SEC Filing  
6/16/2015Axial Capital Master, L.P.Major ShareholderSell7,563,053$3.47$26,243,793.91View SEC Filing  
6/16/2015Jason AryehDirectorBuy288,000$3.47$999,360.00View SEC Filing  
12/22/2014John W KozarichDirectorBuy10,000$3.59$35,900.00View SEC Filing  
12/18/2014Jeffrey A MecklerDirectorBuy20,000$3.60$72,000.00View SEC Filing  
7/11/2014Public Equity K/S NbMajor ShareholderSell1,000,000$5.80$5,800,000.00View SEC Filing  
7/1/2013Axial Capital Master, L.P.Major ShareholderSell288,890$4.39$1,268,227.10View SEC Filing  
6/28/2013Jeffrey A MecklerDirectorBuy30,000$4.36$130,800.00View SEC Filing  
5/14/2013Sukhi JagpalCFOSell10,000$7.95$79,500.00View SEC Filing  
5/13/2013John W KozarichDirectorBuy10,000$7.97$79,700.00View SEC Filing  
5/3/2013Jeffrey A MecklerDirectorBuy20,000$7.96$159,200.00View SEC Filing  
12/28/2012Alexander R LussowVPSell230,000$7.52$1,729,600.00View SEC Filing  
10/5/2012Alexander R LussowVPSell5,000$7.72$38,600.00View SEC Filing  
9/5/2012Alexander R LussowVPSell5,000$7.55$37,750.00View SEC Filing  
8/8/2012Linda LupiniVPSell22,993$7.85$180,495.05View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Novelion Therapeutics (NASDAQ NVLN) News Headlines

Source:
DateHeadline
Novelion Therapeutics (NVLN) Names Michael Price as SVP and CFONovelion Therapeutics (NVLN) Names Michael Price as SVP and CFO
www.streetinsider.com - December 4 at 10:15 AM
What Investors Should Know About Novelion Therapeutics Inc’s (NVLN) Financial StrengthWhat Investors Should Know About Novelion Therapeutics Inc’s (NVLN) Financial Strength
finance.yahoo.com - November 27 at 4:43 PM
Zacks Investment Research Downgrades Novelion Therapeutics Inc. (NVLN) to SellZacks Investment Research Downgrades Novelion Therapeutics Inc. (NVLN) to Sell
www.americanbankingnews.com - November 18 at 6:16 PM
Novelion Therapeutics Inc. (NVLN) Short Interest Up 34.9% in OctoberNovelion Therapeutics Inc. (NVLN) Short Interest Up 34.9% in October
www.americanbankingnews.com - November 13 at 2:32 AM
Novelion Therapeutics reports 3Q lossNovelion Therapeutics reports 3Q loss
finance.yahoo.com - November 12 at 11:08 AM
Should You Buy Novelion Therapeutics Inc (NVLN)?Should You Buy Novelion Therapeutics Inc (NVLN)?
finance.yahoo.com - November 12 at 11:08 AM
Novelion Therapeutics Inc. (NVLN) PT Lowered to $8.00 at Royal Bank Of CanadaNovelion Therapeutics Inc. (NVLN) PT Lowered to $8.00 at Royal Bank Of Canada
www.americanbankingnews.com - November 10 at 3:10 PM
U.S. submits revised plea deal with Novelions Aegerion to courtU.S. submits revised plea deal with Novelion's Aegerion to court
finance.yahoo.com - November 2 at 7:05 AM
U.S. judge says he may reject plea deal with Novelions AegerionU.S. judge says he may reject plea deal with Novelion's Aegerion
finance.yahoo.com - October 19 at 6:59 AM
Zacks: Brokerages Expect Novelion Therapeutics Inc. (NVLN) Will Post Earnings of -$0.29 Per ShareZacks: Brokerages Expect Novelion Therapeutics Inc. (NVLN) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - October 10 at 2:08 AM
Patient assistance charity says U.S. contacted it in probePatient assistance charity says U.S. contacted it in probe
finance.yahoo.com - October 2 at 7:19 PM
Corporate News Blog - Novelions Subsidiary Aegerion Pleads Guilty for Misbranding Juxtapid; Agrees to a Settlement of $40 MillionCorporate News Blog - Novelion's Subsidiary Aegerion Pleads Guilty for Misbranding Juxtapid; Agrees to a Settlement of $40 Million
finance.yahoo.com - October 2 at 7:19 PM
SEC fines pharmaceutical company $4.1 million for misleading performance metricSEC fines pharmaceutical company $4.1 million for misleading performance metric
finance.yahoo.com - September 23 at 8:55 AM
Aegerion finalizes $40M settlement, guilty plea in drug misbranding caseAegerion finalizes $40M settlement, guilty plea in drug misbranding case
finance.yahoo.com - September 23 at 8:55 AM
Novelions Aegerion resolves U.S. drug probes for $40 mlnNovelion's Aegerion resolves U.S. drug probes for $40 mln
finance.yahoo.com - September 23 at 8:55 AM
 Analysts Anticipate Novelion Therapeutics Inc. (NVLN) Will Post Earnings of -$0.29 Per Share Analysts Anticipate Novelion Therapeutics Inc. (NVLN) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - September 21 at 2:26 PM
Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of DirectorsNovelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors
feeds.benzinga.com - September 11 at 9:23 AM
-$0.29 EPS Expected for Novelion Therapeutics Inc. (NVLN) This Quarter-$0.29 EPS Expected for Novelion Therapeutics Inc. (NVLN) This Quarter
www.americanbankingnews.com - August 15 at 12:22 PM
Novelion Therapeutics Reports Second Quarter 2017 Financial ResultsNovelion Therapeutics Reports Second Quarter 2017 Financial Results
globenewswire.com - August 9 at 5:41 AM
Novelion Therapeutics Reports Second Quarter 2017 Financial ResultsNovelion Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 5:41 AM
Novelion Therapeutics reports 2Q lossNovelion Therapeutics reports 2Q loss
finance.yahoo.com - August 9 at 5:41 AM
Novelion Therapeutics Inc. (NASDAQ:NVLN) Posts  Earnings Results, Beats Estimates By $0.01 EPSNovelion Therapeutics Inc. (NASDAQ:NVLN) Posts Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 8 at 2:40 PM
Novelion Therapeutics Inc. (NVLN) Set to Announce Earnings on TuesdayNovelion Therapeutics Inc. (NVLN) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - August 3 at 11:27 AM
Novelion Therapeutics Appoints Mark DiPaolo to Board of DirectorsNovelion Therapeutics Appoints Mark DiPaolo to Board of Directors
finance.yahoo.com - August 3 at 6:27 AM
Novelion Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017Novelion Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017
finance.yahoo.com - July 29 at 5:45 AM
Novelion Therapeutics Inc. (NASDAQ:NVLN) Short Interest Up 78.7% in JuneNovelion Therapeutics Inc. (NASDAQ:NVLN) Short Interest Up 78.7% in June
www.americanbankingnews.com - July 16 at 7:22 AM
Novelion Therapeutics (NVLN) Announces Presentation of Metreleptin Data at ADANovelion Therapeutics (NVLN) Announces Presentation of Metreleptin Data at ADA
www.streetinsider.com - June 14 at 12:05 AM
Novelion Therapeutics (NVLN) Granted Request to Voluntarily Delist from Toronto Stock ExchangeNovelion Therapeutics (NVLN) Granted Request to Voluntarily Delist from Toronto Stock Exchange
www.streetinsider.com - April 19 at 11:59 PM
Novelion Therapeutics (NVLN) Appoints Mark Corrigan to Board of DirectorsNovelion Therapeutics (NVLN) Appoints Mark Corrigan to Board of Directors
www.streetinsider.com - April 2 at 10:46 AM
NOVELION THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExNOVELION THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
biz.yahoo.com - March 31 at 9:06 AM
Novelion Therapeutics (NVLN) to Present New Data on MYALEPT® (metreleptin) at Endocrine Society, 4/1 -4/4Novelion Therapeutics (NVLN) to Present New Data on MYALEPT® (metreleptin) at Endocrine Society, 4/1 -4/4
www.streetinsider.com - March 31 at 12:15 AM
Novelion Therapeutics’ Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine SocietyNovelion Therapeutics’ Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society
us.rd.yahoo.com - March 30 at 7:14 PM
NOVELION THERAPEUTICS INC. Files SEC form 10-K, Annual ReportNOVELION THERAPEUTICS INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 30 at 7:14 PM
Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial ResultsNovelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results
us.rd.yahoo.com - March 15 at 9:46 AM
NOVELION THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors orNOVELION THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or
us.rd.yahoo.com - March 15 at 9:46 AM
Novelion Therapeutics to Announce Preliminary Fourth Quarter and Full Year 2016 Financial Results on March ...Novelion Therapeutics to Announce Preliminary Fourth Quarter and Full Year 2016 Financial Results on March ...
globenewswire.com - March 13 at 6:38 PM
Novelion Therapeutics Announces Presentation at the 29th Annual ROTH Conference - GlobeNewswire (press release)Novelion Therapeutics Announces Presentation at the 29th Annual ROTH Conference - GlobeNewswire (press release)
globenewswire.com - March 8 at 7:43 PM
U.S. Patent Trial and Appeal Board Affirms Lomitapide Patents with Favorable IPR DecisionsU.S. Patent Trial and Appeal Board Affirms Lomitapide Patents with Favorable IPR Decisions
us.rd.yahoo.com - March 7 at 10:01 AM
Novelion Therapeutics (NVLN) Noses Forward on Rare Disease DayNovelion Therapeutics (NVLN) Noses Forward on Rare Disease Day
www.msn.com - February 28 at 10:37 AM
Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines AgencyNovelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency
us.rd.yahoo.com - January 23 at 9:47 AM
Novelion Therapeutics Reports Preliminary 2016 Net Product Sales and Provides 2017 OutlookNovelion Therapeutics Reports Preliminary 2016 Net Product Sales and Provides 2017 Outlook
us.rd.yahoo.com - January 10 at 12:40 AM
NOVELION THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other EventsNOVELION THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events
biz.yahoo.com - January 9 at 7:38 PM
NOVELION THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial StaNOVELION THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Sta
biz.yahoo.com - January 3 at 11:15 PM
Splits Calendar: Novelion splits before market open today (1:5 ratio)Splits Calendar: Novelion splits before market open today (1:5 ratio)
biz.yahoo.com - December 19 at 9:20 AM
NOVELION THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsNOVELION THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - December 16 at 7:39 PM
Aegerion Pharmaceuticals, a Subsidiary of Novelion Therapeutics, Enters into Agreement in Principle to Settle Class ... - GlobeNewswire (press release)Aegerion Pharmaceuticals, a Subsidiary of Novelion Therapeutics, Enters into Agreement in Principle to Settle Class ... - GlobeNewswire (press release)
globenewswire.com - December 7 at 6:53 PM
QLT INC/BC FinancialsQLT INC/BC Financials
us.rd.yahoo.com - December 6 at 6:41 PM
QLT INC/BC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity SecuriQLT INC/BC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securi
biz.yahoo.com - December 6 at 9:38 AM
3:07 am Novelions Aegerion unit enters into licensing agreement with Amryt Pharma; provides new royalty and potential milestone revenues3:07 am Novelion's Aegerion unit enters into licensing agreement with Amryt Pharma; provides new royalty and potential milestone revenues
us.rd.yahoo.com - December 5 at 6:55 PM

SEC Filings

Novelion Therapeutics (NASDAQ:NVLN) SEC Filings

DateFilerForm TypeView
12/08/2017
3:29 PM
Chan Barbara Y (Reporting)
Novelion Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/08/2017
10:29 AM
EdgePoint Investment Group Inc. (Filed by)
Novelion Therapeutics (Subject)
Form SC 13G
View Filing
12/06/2017
3:03 PM
Novelion Therapeutics (Issuer)
PRICE MICHAEL DENNIS (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
View Filing
11/29/2017
3:04 PM
Novelion Therapeutics (Issuer)
Stewart Murray (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
11/29/2017
3:02 PM
Novelion Therapeutics (Issuer)
Stewart Murray (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
View Filing

Social Media

Financials

Novelion Therapeutics (NASDAQ:NVLN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novelion Therapeutics (NASDAQ NVLN) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.